Heartland Bank & Trust Co Makes New $254,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Heartland Bank & Trust Co bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,202 shares of the medical research company’s stock, valued at approximately $254,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rise Advisors LLC purchased a new stake in IQVIA in the first quarter worth $31,000. Versant Capital Management Inc increased its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the period. Riverview Trust Co purchased a new position in shares of IQVIA during the first quarter valued at $32,000. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the second quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the second quarter valued at $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on IQV. Evercore ISI raised their price target on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. raised their price target on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays raised their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Price Performance

Shares of NYSE IQV opened at $236.97 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market cap of $43.20 billion, a PE ratio of 32.37, a P/E/G ratio of 2.25 and a beta of 1.49. The business has a 50-day simple moving average of $241.32 and a two-hundred day simple moving average of $233.07. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period last year, the business posted $2.22 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.